Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6952412 | 0.88 | ESR1 (0.55) | MAPTSMN1; SMN2ALDH1A1HPGDALOX15 | |
| SCHEMBL22096860 | 0.80 | MAPT (0.62) | MAPTSMN1; SMN2ALDH1A1HPGDALOX15 | |
| SCHEMBL332380 | 0.80 | MAPT (0.62) | MAPTSMN1; SMN2ALDH1A1HPGDALOX15 | |
| SCHEMBL11417093 | 0.78 | MAPT (0.61) | MAPTSMN1; SMN2ALDH1A1HPGDALOX15 | |
| SCHEMBL14198060 | 0.78 | MAPT (0.61) | MAPTSMN1; SMN2ALDH1A1HPGDALOX15 | |
| SCHEMBL32671491 | 0.78 | MAPT (0.42) | MAPTSMN1; SMN2ALDH1A1HPGDALOX15 | |
| SCHEMBL183161 | 0.78 | MAPT (0.42) | MAPTSMN1; SMN2ALDH1A1HPGDALOX15 | |
| SCHEMBL11521420 | 0.77 | MAPT (1.00) | MAPTSMN1; SMN2ALDH1A1HPGDALOX15 | |
| SCHEMBL11521418 | 0.77 | MAPT (1.00) | MAPTSMN1; SMN2ALDH1A1HPGDALOX15 | |
| SCHEMBL16472974 | 0.77 | MAPT (1.00) | MAPTSMN1; SMN2ALDH1A1HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114950551-B | Monophosphite polymer catalyst for olefin hydroformylation, preparation method and application thereof | 中国海洋石油集团有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-116462801-A | Bidentate phosphite polymer, preparation method and application thereof, and method for synthesizing olefin carbonyl | 山东京博石油化工有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-114950551-A | Monophosphite polymer catalyst for olefin hydroformylation and preparation method and application thereof | 中国海洋石油集团有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | MAPT 3880/4885SMN1; SMN2 3746/4885ALDH1A1 451/4885 |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | CCR3, CCR1, CCR4 | MAPT 3081/4885SMN1; SMN2 4687/4885ALDH1A1 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.